ClinicalTrialsFinder
RecruitingPhase 1Phase 2NCT06811870

A Phase II Single-Arm Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Breast Cancer Patients

Sponsor

Guangdong Provincial People's Hospital

Enrollment

161 participants

Start Date

Feb 1, 2025

Study Type

INTERVENTIONAL

Conditions

Breast Cancers

Summary

The goal of the study is to explore the efficacy and safety of hyperbaric oxygen in the neoadjuvant treatment of breast cancer patients

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 60 Years

Inclusion Criteria10

  • Understand the study process, participate in the study voluntarily, and sign the informed consent form.
  • patients with histopathologically confirmed initial unilateral primary invasive breast cancer, occult breast cancer, Patients with histopathologically confirmed initial unilateral primary invasive breast cancer, with the exception of occult breast cancer, inflammatory breast cancer and eczema-like carcinoma
  • aged ≥ 18 years and ≤ 60 years, female
  • ECOG performance status 0-1. 6.
  • LVEF ≥ 55% 7.
  • Adequate bone marrow functional reserve: white blood cell count ≥3.0 x 109/L, neutrophil count ≥1.5 x 109/L; and 1.5 x 109/L; platelet count ≥ 100 x 109/L; haemoglobin ≥ 90 g/L;
  • AST, ALT ≤ 2.5 times the upper limit of normal value, alkaline phosphatase ≤ 2.5 times the upper limit of normal value.
  • Total bilirubin ≤ 1.5 times the upper limit of normal value; serum creatinine ≤ 1.5 times the upper limit of normal value.
  • For non-menopausal or non-surgically sterilised female patients: during treatment and at least 7 months after the last dose of study treatment.
  • For non-menopausal or non-surgically sterilised female patients: consent to contraception during treatment and for at least 7 months after the last dose of study treatment.

Exclusion Criteria13

  • Contraindication to hyperbaric oxygen therapy: untreated pneumothorax. Concurrent use of disulfiram. concomitant administration of anti-tumour drugs such as bleomycin, cisplatin, adriamycin concomitant administration of antineoplastic drugs such as bleomycin, cisplatin, adriamycin. Premature and/or low body mass neonates. Lung disease (severe chronic obstructive pulmonary disease).
  • Diseases of the lungs (severe chronic obstructive airway disease, herpetic lung disease, acute or chronic lung infections, uncontrolled asthma, uncontrolled diarrhoea).
  • controlled asthma, untreated pneumothorax), history of previous middle ear surgery, middle ear disease (eustachian tube Dysfunction of the eustachian tube, recurrent episodes of vertigo), ocular disease (retinal detachment).
  • previous hyperbaric oxygen therapy.
  • distant metastases, including lymph node metastases to the contralateral breast and mediastinum.
  • other malignant tumours within the last two years, except for radically treated basal or squamous cell carcinoma of the skin or CIS of the cervix.
  • Tumour.
  • pregnancy or lactation
  • uncontrolled hypertension, cardiac, hepatic, renal related disease or other medical or psychiatric conditions.
  • major surgical procedure unrelated to breast cancer within 4 weeks prior to randomisation, or the patient has not fully recovered from such procedure; or has not fully recovered from such surgical intervention.
  • serious or uncontrolled infections that may interfere with study treatment or assessment of study results, including but not limited to Serious or uncontrolled infections that may interfere with study treatment or the evaluation of study results, including but not limited to active hepatitis virus infection, human immunodeficiency virus (HIV) antibody positivity, and pulmonary infections.
  • recent history of thromboembolism and taking full dose anticoagulant medication.
  • any other condition that, in the opinion of the investigator, makes the patient unsuitable for participation in the study

Interventions

DEVICEhyperbaric oxygen treatment

Patients who meet the inclusion criteria will be enrolled and given hyperbaric oxygen intervention, with a minimum of 5 hyperbaric oxygen treatments per chemotherapy cycle, one per day for 60-90 minutes, for a total of 30-40 hyperbaric oxygen treatments (100% oxygen at a pressure of 2.0 ATA).

Locations(2)

Guangdong Provincial People's Hospital

Guangzhou, Guangdong, China

Guangdong Provincial People's Hospital

Shantou, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06811870

Related Trials

Partial Breast Re-irradiation for Breast Cancer

NCT069546231 location

Tirzepatide Weight Loss for MRD+ Early Breast Cancer

NCT065172121 location

Sustainable Implementation of the EXCEL Exercise Oncology Program Across Canada

NCT069602915 locations

Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer

NCT066067302 locations

Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer

NCT070950239 locations